公开(公告)号：US20210353730A1

公开(公告)日：2021-11-18

申请号：US17391694

申请日：2021-08-02

申请人： NantCell, Inc. ,  Nant Holdings IP, LLC

发明人： Patrick Soon-Shiong ,  Kayvan NIAZI ,  Shahrooz RABIZADEH ,  Hans G. Klingemann ,  Laurent H. Boissel ,  Barry J. Simon

IPC分类号： A61K39/00 ,  A61K38/20 ,  C07K16/28

摘要： Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.

公开(公告)号：US11207392B2

公开(公告)日：2021-12-28

申请号：US16312246

申请日：2017-06-30

申请人： Nant Holdings IP, LLC ,  NANTCELL, INC.

发明人： Patrick Soon-Shiong ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Hans G. Klingemann ,  Laurent H. Boissel ,  Barry J. Simon

IPC分类号： A61K39/00 ,  A61K38/20 ,  C07K16/28

摘要： Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.

公开(公告)号：US11439697B2

公开(公告)日：2022-09-13

申请号：US17391694

申请日：2021-08-02

申请人： NantCell, Inc. ,  Nant Holdings IP, LLC

发明人： Patrick Soon-Shiong ,  Kayvan Niazi ,  Shahrooz Rabizadeh ,  Hans G. Klingemann ,  Laurent H. Boissel ,  Barry J. Simon

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K38/20 ,  C07K16/28

摘要： Cancer is treated using coordinated treatment regimens that uses various compounds and compositions that drive a tumor from the escape phase of cancer immunoediting to the elimination and equilibrium phase of cancer immunoediting.

公开(公告)号：US11221328B2

公开(公告)日：2022-01-11

申请号：US16491559

申请日：2018-03-07

申请人： NANTCELL, INC.

发明人： Patrick Soon-Shiong ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Stephen Charles Benz ,  Laurent H. Boissel ,  Hans Klingemann ,  Barry J. Simon

IPC分类号： C12Q1/6886 ,  G01N33/50 ,  G16H50/30 ,  C12N5/0783

摘要： Detection of under-expression of selected genes in NK cells is used to confirm a hypoxic tumor microenvironment that is ordinarily suppressive with respect to ADCC and cytotoxic cell killing of NK cells. Most notably, while hypoxia is known to upregulate HIF-1α and genes under the control of HIF-1α, hypoxia in a tumor microenvironment led to under-expression of selected genes, including HIF-1α. Thus, gene expression analysis of certain genes on NK cells can be used to detect conditions in a tumor that would indicate use of haNK cells.